KIR3DL1 and acute myeloid leukemia: Of notice, two studies from Japan observed that the lack of the HLA-C2 ligand for donor inhibitory KIR afforded relapse protection in patients with AML and chronic myeloid leukemia, but increased the relapse rate in patients with ALL (73, 75).